Serum CXCL10 as a potential biomarker for lupus nephritis and disease activity: evidence from an Egyptian cohort Authors: Fatma Mohammed Badr, Dalia Mohamed Gamal, Ghada Maged Mohsen, Mohammed Abd El Monem Teama Published: 2026 ABSTRACT BackgroundSerum CXCL10 is one of the chemokines that is strongly associated with systemic lupus erythematosus (SLE) and its related complications, particularly lupus nephritis (LN). Our study aimed to validate serum CXCL10 as a potential biomarker of LN and disease activity, and to assess its association with organ damage in Egyptian patients.MethodsA cross-sectional study was conducted among 100 SLE patients recruited from Ain Shams University Hospital, with 50 patients in group I (without LN) and 50 in group II (with LN). All patients underwent a medical history review, clinical examination, and assessment of disease activity using the SLE Disease Activity Index (SLEDAI-2K) and the Renal SLEDAI (R-SLEDAI). Damage scores were recorded for each patient. Laboratory investigations, such as serum CXCL10, complete blood count (CBC), blood urea nitrogen (BUN), serum creatinine, estimated glomerular filtration rate (eGFR), urine analysis, 24-h urinary protein excretion, antinuclear antibodies (ANA), anti-dsDNA antibodies, and serum complement (C3, C4).ResultsSerum CXCL10 levels were significantly elevated in patients with LN compared to those without (p < 0.001). Disease activity indices, renal function parameters, and damage scores were all increased in the LN group (p < 0.001). CXCL10 levels demonstrated strong positive correlations with 24-hour urinary protein, BUN, serum creatinine, disease activity and damage scores, and strong negative correlations with eGFR, C3, and C4 (all p < 0.001). Diagnostic accuracy analyses showed that serum CXCL10 predicted LN with 96% sensitivity and 94% specificity and was also predictive of renal and overall disease activity (sensitivity/specificity for R-SLEDAI: 100%/94.2%; for SLEDAI-2K: 81.97%/97.44%).ConclusionSerum CXCL10 is a promising non-invasive biomarker for identifying LN and monitoring disease activity in SLE patients. Background SLE is a chronic autoimmune disease that primarily affects women who are of reproductive age. In clinical practice, SLE frequently poses diagnostic and therapeutic issues due to its multisystem involvement and diverse clinical symptoms [1]. About 50% of adult SLE patients develop LN, one of the most severe consequences, which greatly increases long-term morbidity and death [2]. Composite indicators like the SLE Disease Activity Index (SLEDAI) and its renal component (R-SLEDAI) are commonly used to evaluate LN. However, because clinical and laboratory indications may be ambiguous, it is still challenging to distinguish renal involvement from systemic disease activity. Renal biopsy is still the gold standard for identifying and categorizing LN, but its clinical relevance is limited by its invasiveness, hazards, and inability to be repeated often. To help with the early diagnosis and monitoring of LN activity, trustworthy, non-invasive biomarkers are therefore desperately needed [3]. Interferon-gamma (IFN-γ), a pro-inflammatory cytokine mostly produced by T-helper 1 (Th1) cells, is crucial in the pathogenesis of SLE and is associated with the onset and advancement of LN [4]. C-X-C motif ligands, specifically CXCL9, CXCL10 (often referred to as IP-10), and CXCL11, are notable IFN-inducible chemokines recognized for their capacity to attract immune cells to inflammatory areas. These chemokines utilize a shared receptor, CXCR3, which is present on activated T cells, natural killer (NK) cells, dendritic cells, and plasma-like cells [5, 6] Recent evidence indicates that CXCL10 levels are markedly increased in the serum and urine of individuals with active lupus nephritis, correlating with disease activity and renal histopathological abnormalities [7, 8]. Furthermore, the simultaneous assessment of CXCL9, CXCL10, and CXCL11 has been documented to improve the diagnostic sensitivity and specificity for LN in individuals with SLE [8]. Despite a comprehensive investigation, there is a paucity of data about the correlation between blood CXCL10 levels and cumulative organ damage in SLE. Methods Aim of the study This study aimed to evaluate the clinical utility of serum CXCL10 as a potential biomarker for LN, overall disease activity, and cumulative organ damage in a cohort of Egyptian patients with SLE. Study design and setting This cross-sectional study was conducted on adult SLE patients who were recruited from the inpatient wards and outpatient rheumatology clinic of Ain Shams University Hospital, Cairo, Egypt, during the selection period from May to November 2025. Patients The study included 100 patients with SLE aged ≥ 18 years, classified according to the Systemic Lupus International Collaborating Clinics (SLICC) criteria [9]. Patients were categorized into two groups according to the presence of LN: Group I comprised 50 SLE patients without LN, and Group II comprised 50 SLE patients with LN. SLE patients were diagnosed with LN based on one or more of the following clinical and laboratory criteria:Proteinuria > 0.5 g/24 h, or ≥3+ protein on dipstick in a random urine sample, or a urine protein/creatinine ratio > 500 mg/g (50 mg/mmol).Presence of cellular casts, including red blood cells, hemoglobin, granular, tubular, or mixed casts.Active urine sediments (in the absence of urinary tract infection), defined as white blood cells > 5/high-power field (HPF) or red blood cells > 5/HPF, and/or red blood cell or white blood cell casts. Proteinuria > 0.5 g/24 h, or ≥3+ protein on dipstick in a random urine sample, or a urine protein/creatinine ratio > 500 mg/g (50 mg/mmol). Proteinuria > 0.5 g/24 h, or ≥3+ protein on dipstick in a random urine sample, or a urine protein/creatinine ratio > 500 mg/g (50 mg/mmol). Presence of cellular casts, including red blood cells, hemoglobin, granular, tubular, or mixed casts. Presence of cellular casts, including red blood cells, hemoglobin, granular, tubular, or mixed casts. Active urine sediments (in the absence of urinary tract infection), defined as white blood cells > 5/high-power field (HPF) or red blood cells > 5/HPF, and/or red blood cell or white blood cell casts. Active urine sediments (in the absence of urinary tract infection), defined as white blood cells > 5/high-power field (HPF) or red blood cells > 5/HPF, and/or red blood cell or white blood cell casts. Renal biopsy was performed in patients fulfilling the clinical and laboratory criteria for LN (all 50 patients in Group II were biopsy-confirmed), and histopathological examination was used to determine the corresponding LN class. Exclusion criteria Patients were excluded if they had significant comorbidities, including cardiovascular disease, chronic liver disease or viral hepatitis, or renal disorders unrelated to SLE. Pregnant or lactating women were excluded. Patients with hematologic disorders unrelated to SLE, endocrine abnormalities, other rheumatic diseases (such as rheumatoid arthritis or systemic sclerosis), mixed connective tissue disease, other autoimmune conditions, or malignancies were also excluded. Ethical considerations The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of the Faculty of Medicine, Ain Shams University (FMASU REC; approval number FW00017585/R 305/2025). Written informed consent was obtained from all participants before enrolment, after explanation of the study objectives and procedures. Clinical and laboratory assessment For all participants, demographic data (age, sex), disease duration, and detailed clinical history were recorded. Complete clinical and rheumatological examinations were performed. Laboratory assessments included measurement of C-reactive protein (CRP), kidney function tests (BUN, serum creatinine), and CBC using automated analyzers. Erythrocyte sedimentation rate (ESR) was determined by the Westergren method. Urinalysis comprised evaluation of protein, red and white blood cells, and urinary casts. Twenty-four-hour proteinuria was quantified for all patients. eGFR was calculated by the Modification of Diet in Renal Disease (MDRD) formula [10]: \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$\begin{aligned}& \mathrm{eGFR}\:(\mathrm{mL/min/1.73\:m2})\cr & \:=186 \times (\mathrm{serum\:creatinine/88.4})\cr & \:-1.154 \times (\mathrm{age})-0.203 \cr & \: \times 0.742\:(\mathrm{if\:female}) \times 1.210\:(\mathrm{if\:black})\end{aligned}$$\end{document} For patients with LN (all 50 patients in Group II were biopsy-confirmed), renal biopsies were performed to determine the activity index (AI) and chronicity index (CI). Histopathological classification of LN followed the updated criteria of the International Society of Nephrology/Renal Pathology Society (ISN/RPS) [11]. Immunological workup comprised lupus anticoagulant analysis, ANA detection by indirect immunofluorescence, anti-double-stranded DNA (anti-dsDNA) antibody quantification by fluorescence enzyme immunoassay (FEIA) (cut-off: 10 IU/mL), anti-cardiolipin antibodies measured by ELISA, and serum complement C3/C4 quantified using automated chemistry analyzers. Biomarker assessment Fasting venous blood (10 mL) was obtained from each subject between 8:00 AM and 10:00 AM to minimize diurnal variability. After centrifugation at 3000 rpm for 15 minutes, serum was separated and stored at − 80 °C until analysis. Serum CXCL10 concentrations were measured using a commercially available sandwich ELISA kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s instructions. To ensure assay reproducibility, all samples were analyzed in duplicate. The intra-assay and inter-assay coefficients of variation (CV) were 3.1% and 6.7%, respectively. Furthermore, patients with any clinical or laboratory evidence of active infection (viral, bacterial, or fungal) were excluded at the time of sampling to avoid confounding of the IFN-inducible chemokine levels. Disease activity assessment Global SLE disease activity was assessed using the SLE Disease Activity Index-2000 (SLEDAI-2K) [12]. SLEDAI-2 K scores were categorized as follows: • SLEDAI = 20 indicates very high activity, • SLEDAI = 11–19 indicates high activity, • SLEDAI = 6–10 indicates moderate activity, • SLEDAI = 1–5 indicates mild activity, • SLEDAI = 0 indicates no activity Renal disease activity was assessed using the Renal SLEDAI (R-SLEDAI), which ranges from 0 to 16, where 0 indicates inactive LN. R-SLEDAI is calculated as the sum of four renal items from SLEDAI; if present, each item—proteinuria > 0.5 g/day, hematuria > 5 red blood cells/HPF, pyuria > 5 white blood cells/HPF, and cellular casts receives a score of 4 [13]. Assessment of cumulative organ damage Cumulative organ damage was assessed using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index (SDI). This index records irreversible damage attributed to SLE or its treatment that has been present for at least six months (except for myocardial infarction and stroke). Damage is scored in 12 organ systems: malignancy (0–2), gonadal (0–1), endocrine (diabetes) (0–1), skin (0–3), musculoskeletal (0–7), gastrointestinal (0–6), peripheral vascular (0–5), cardiovascular (0–6), pulmonary (0–5), renal (0–3), neuropsychiatric (0–6), and ocular (0–2). The total SDI score ranges from 0 to 47, with higher scores indicating greater cumulative damage [14]. Statistical analysis Data was entered and analyzed using IBM SPSS Statistics, version 27 (IBM Corp., Armonk, NY, USA). Quantitative variables were tested for normality and are presented as mean ± standard deviation (SD) and range for normally distributed data or median and interquartile range (IQR) for non-normally distributed data. Categorical variables are presented as frequencies and percentages. Comparisons between two independent groups were performed using the Student’s t test for normally distributed variables and the Mann–Whitney U test for non-normally distributed variables. For comparisons among more than two groups, one-way analysis of variance (ANOVA) or the Kruskal–Wallis test was used, as appropriate. Associations between categorical variables were assessed using the chi-square test or Fisher’s exact test when expected counts were < 5 in more than 20% of cells. Correlations between continuous variables were evaluated using Pearson’s correlation coefficient for normally distributed data and Spearman’s rho for non-normally distributed data. Multivariable logistic regression analysis was performed to identify independent predictors of categorical outcomes, and adjusted odds ratios with 95% confidence intervals were reported. Variable selection for the multivariate logistic regression model was based on a combination of statistical significance in univariate analysis (p < 0.1) and clinical relevance. A backward elimination process was then applied to arrive at the most parsimonious model. The association between serum CXCL10 and lupus nephritis was initially analyzed using raw concentration values (per 1 pg/mL). However, to facilitate clinical application, the odds ratios (OR) and 95% confidence intervals (CI) were post hoc rescaled and are reported per 10 pg/mL increase. This transformation was applied to both univariate and multivariate results to ensure consistency in reporting across the study. Multicollinearity among the independent variables was evaluated using the Variance Inflation Factor (VIF); a VIF value > 5 was considered indicative of significant multicollinearity. No variables in the final model exceeded this threshold. The diagnostic performance of serum CXCL10 for LN and for disease activity indices was assessed by receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) was interpreted as follows: excellent (0.90–1.00), good (0.80–0.89), fair (0.70–0.79), poor (0.60–0.69), and fail (<0.60). Sensitivity and specificity were expressed as percentages. To assess the internal validity of our ROC analysis and control for potential overfitting, we performed a bootstrapping procedure with 1,000 resamples to calculate the validated AUC and 95% Confidence Intervals (CI). To determine the added value of CXCL10 to clinical markers, we constructed a Base Model (24 h urinary protein, eGFR, C3, C4, and SLEDAI-2K) and a Full Model (Base Model + CXCL10). The AUCs of these models were statistically compared using the DeLong test to evaluate if the inclusion of CXCL10 significantly improved diagnostic performance. The level of statistical significance was set as follows:p > 0.050: not significant (NS)p < 0.050: significant (S)p ≤ 0.001: highly significant (HS) p > 0.050: not significant (NS) p > 0.050: not significant (NS) p < 0.050: significant (S) p < 0.050: significant (S) p ≤ 0.001: highly significant (HS) p ≤ 0.001: highly significant (HS) Results Upon comparing the demographic data of the two groups, a significant disparity was observed in sex, with a larger prevalence of men in group II (p = 0.003). Conversely, no significant differences were noted in age or disease duration, as illustrated in Table 1. Clinical data revealed that serositis, neuropsychiatric, and pulmonary symptoms were significantly more prevalent in Group II (p < 0.001, 0.004, <0.001), as shown in Table 1. Group II had elevated levels of 24-hour urine protein, anemia, BUN, serum creatinine, and reduced complement levels, as well as active urinary sediment (casts, hematuria, pyuria), albuminuria, and anti-DNA antibodies compared to Group I. Conversely, eGFR was markedly reduced in group II relative to group I. Only Group II reported renal biopsy classifications and their histological categorization using both AI and CI. The LN group was defined based on both clinical/laboratory criteria and renal biopsy findings. Group II patients had markedly elevated disease activity scores (both SLEDAI-2K and R-SLEDAI) in comparison to Group I (p < 0.001). The serum CXCL10 level was markedly elevated in group II (p < 0.001). Analysis of drug intake frequency shows that Prednisolone and Hydroxychloroquine were foundational treatments used by 100% of all patients. A clear therapeutic divergence emerged regarding intensive therapies: Cyclophosphamide (52% vs. 8% p < 0.001) and Mycophenolate mofetil (44% vs. 6% p < 0.001) were highly significantly associated with the LN group. While Azathioprine was more common in the non-LN group (p = 0.051). Rituximab was used only in the LN group (p = 0.083). These differences were not statistically significant. Table 1Comparison between two groups as regards demographic data, cumulative clinical data, laboratory data, disease activity scores, and level of serum CXCL10Total study group(n= 100)GroupsTest of significanceGroup ISLE patients without nephritis (n= 50)Group IILupus nephritis (LN) patients (n= 50)Mean ± SDRangeMean ± SDRangeMean ± SDRangevaluep-valuesig.Age (years)29.4 ± 8.58(15 - 58)28.78 ± 7.68(15 - 45)30.02 ± 9.44(18 - 58)t= -0.7210.473NSSex (N, %)Male21 (21%)4 (8%)17 (34%)FE0.003SFemale79 (79%)46 (92%)33 (66%)Disease duration (Years)Median (IQR)Range3 (2 - 5.5)(1 - 15)3 (2 - 5)(1 - 11)4.5 (3 - 6)(1 - 15) z= -1.5610.119NSMalar rash95 (95%)45 (90%)50 (100%)FE0.056NSOral ulcer87 (87%)40 (80%)47 (94%)FE0.071NSMusculoskeletalManifestationNegative2 (2%)1 (2%)1 (2%)FE0.361NSPoly Arthritis24 (24%)9 (18%)15 (30%)Poly Arthralgia74 (74%)40 (80%)34 (68%)Photosensitivity49 (49%)24 (48%)25 (50%)X2 = 0.040.841NSAlopecia51 (51%)29 (58%)22 (44%)X2 = 1.9610.161NSConstitutional symptoms80 (80%)43 (86%)37 (74%)X2 = 2.250.134NSSerositis (pleural or pericardial effusion)39 (39%)11 (22%)28 (56%)X2 = 12.15<0.001HSNeuropsychiatric manifestations22 (22%)5 (10%)17 (34%)X2 = 8.3920.004SRecurrent thrombosis12 (12%)8 (16%)4 (8%)FE0.357NSBleeding tendency6 (6%)5 (10%)1 (2%)FE0.204NSCardiac manifestation20 (20%)7 (14%)13 (26%)X2 = 2.250.134NSPulmonary manifestations33 (33%)8 (16%)25 (50%)X2 = 13.07<0.001STLC x 103 /µL5.26 ± 2.3(1.8 - 13)5.53 ± 2.27(2.7 - 13)5 ± 2.34(1.8 - 13)t= 1.1430.256NSNeutrophils x 103 /µL3.24 ± 1.47(1 - 8)3.32 ± 1.5(1 - 7)3.17 ± 1.44(1 - 8)t= 0.5130.609NSLymphocytes x 103 /µL1.38 ± 0.68(0.2 - 3.5)1.43 ± 0.59(0.2 - 3)1.33 ± 0.76(0.5 - 3.5)t= 0.7480.456NSHGB (g/dL)10.42 ± 1.56(7.2 - 13.8)10.88 ± 1.48(7.2 - 13.8)9.96 ± 1.51(7.5 - 13)t= 3.0860.003SPLT x 103 /µL231.27 ± 80.38(25 - 452)218.5 ± 79.29(25 - 406)244.04 ± 80.22(105 - 452)t= -1.6010.113NSESR (mm/hr)(Median (IQR))40 (30 - 60)(5 - 140)30 (22 - 40)(5 - 140)60 (40 - 60)(13 - 140)z= -4.379<0.001HSCRP (mg/L)(Median (IQR))6 (6 - 12)(0.4 - 96)6 (4 - 6)(0.4 - 56)12 (6 - 48)(4 - 96)z= -5.373<0.001HSUrine analysisRed Blood cells (RBCS)2 (1 - 3)(0 - 6)2 (1 - 2)(0 - 4)2 (1 - 4)(0 - 6)z= -2.8610.004SPus cells3 (2 - 3)(0 - 8)2 (1 - 3)(0 - 4)3 (3 - 5)(0 - 8)z= -5.405<0.001HS Urinary Casts(N, %)NIL85 (85%)50 (100%)35 (70%)FE<0.001HSPositive15 (15%)0 (0%)15 (30%)Albumin(N, %) by dipstickNIL47 (47%)45 (90%)2 (4%)FE<0.001HS(+)20 (20%)5 (10%)15 (30%)(++)22 (22%)0 (0%)22 (44%)(+++)11 (11%)0 (0%)11 (22%)24-hour Urinary proteins (mg/24h)400 (150 - 1000)(100 - 12000)200 (100 - 200)(100 - 400)1000 (600 - 2000)(100 - 12000)z= -8.180<0.001HSBUN (mg/dL)21.47 ± 10.55(12 - 98)18.74 ± 1.26(15 - 22)24.2 ± 14.43(12 - 98)t= -2.6650.010SSerum creatinine (mg/dL)1.07 ± 1.13(0.3 - 5.5)0.6 ± 0.17(0.3 - 1)1.53 ± 1.46(0.4 - 5.5)t= -4.487<0.001HSeGFR (mL/min/1.73m2)80.87 ± 19.85(25 - 96)88.96 ± 7.25(72 - 96)72.78 ± 24.7(25 - 96)t= 4.445<0.001HSC3 (mg/dL)95.5 (65.5 - 134)(27 - 170)121 (95 - 135)(27 - 169)69 (62 - 96)(45 - 170)z= -4.748<0.001HSC4 (mg/dL)13.5 (8 - 22)(5 - 42)22 (14 - 23)(5 - 42)8 (6 - 12)(6 - 33)z= -5.883<0.001HSLACNegative91 (91%)43 (86%)48 (96%)FE0.16NSPositive9 (9%)7 (14%)2 (4%)A.C. LNegative93 (93%)45 (90%)48 (96%)FE0.436NSPositive7 (7%)5 (10%)2 (4%)Anti DNANegative8 (8%)5 (10%)3 (6%)FE0.715NSPositive92 (92%)45 (90%)47 (94%)Anti DNA (IU/mL)22.97 ± 7.76(10 - 36)18.02 ± 4.77(10 - 34)27.92 ± 6.99(10 - 36)t= -8.277<0.001HSANANegative1 (1%)1 (2%)0 (0%)FE1.00NSPositive99 (99%)49 (98%)50 (100%)Renal biopsy Classes(N, %)Not done50 (50%)50 (100%)0 (0%)FE<0.001HSClass II3 (6%)0 (0%)3 (6%)Class III18 (36%)0 (0%)18 (36%)Class IV13 (26%)0 (0%)13 (26%)Class V13(26%)0 (0%)13(26%)Class VI3 (6%)0 (0%)3 (6%)A.I (/24)0 (0 - 2)(0 - 12)0 (0 - 0)(0 - 1)2 (0 - 7)(0 - 12)z= -6.075<0.001HSC.I (/12)0 (0 - 1)(0 - 8)0 (0 - 0)(0 - 1)1 (0 - 2)(0 - 8)z= -5.898<0.001HSR-SLEDAI0 (0 - 8)(0 - 12)0 (0 - 0)(0 - 0)8 (4 - 8)(0 - 12)z= -9.037<0.001HSSLEDAI-2K SCORE6 (1 - 10)(0 - 16)1 (0 - 4)(0 - 11)10 (8 - 11)(0 - 16)z= -7.142<0.001HSSLEDAI-2K SCORE (N, %)In active (0)23 (23%)42 (84%)1 (2%)FE<0.001HSMild (1 – 5)22 (22%)3 (6%)2 (4%)Moderate (6 – 10)32 (32%)5 (10%)27 (54%)Severe (11 - 19)23 (23%)0 (0%)20 (40%)CXCL10 (pg/mL)217.39 ± 124.82(50 - 580)121 ± 40.61(50 - 220)313.78 ± 104.24(120 - 580)t= -12.185<0.001HSFrequency of drug intake (N, %)Prednisolone (N, %)100 (100%)50 (100%)50 (100%)N/AN/A---Hydroxychloroquine (N, %)100 (100%)50 (100%)50 (100%)N/AN/A---Azathioprine (N, %)85 (85%)46 (92%)39 (78%)t = 1.980.051NSCyclophosphamide (N, %)30 (30%)4 (8%)26 (52%)t=-5.42< 0.001HSMycophenolate mofetil (N, %)25 (25%)3 (6%)22 (44%)t=-4.78< 0.001HSRituximab (N, %)3 (3%)0 (0%)3 (6%)t=-1.770.083NSP value > 0.05: non-significant (NS); P value < 0.05: significant (S); P value < 0.01: highly significant (HS)TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, LAC lupus anticoagulant, ACL Anticardiolipin, ANA antinuclear antibody, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity scoreSLEDAI-2K systemic lupus erythematosus disease activity scoreFisher’s Exact test of significance (FE). Mann-Whitney test of significance (z). Chi-Square test of significance (X2) Table 1Comparison between two groups as regards demographic data, cumulative clinical data, laboratory data, disease activity scores, and level of serum CXCL10Total study group(n= 100)GroupsTest of significanceGroup ISLE patients without nephritis (n= 50)Group IILupus nephritis (LN) patients (n= 50)Mean ± SDRangeMean ± SDRangeMean ± SDRangevaluep-valuesig.Age (years)29.4 ± 8.58(15 - 58)28.78 ± 7.68(15 - 45)30.02 ± 9.44(18 - 58)t= -0.7210.473NSSex (N, %)Male21 (21%)4 (8%)17 (34%)FE0.003SFemale79 (79%)46 (92%)33 (66%)Disease duration (Years)Median (IQR)Range3 (2 - 5.5)(1 - 15)3 (2 - 5)(1 - 11)4.5 (3 - 6)(1 - 15) z= -1.5610.119NSMalar rash95 (95%)45 (90%)50 (100%)FE0.056NSOral ulcer87 (87%)40 (80%)47 (94%)FE0.071NSMusculoskeletalManifestationNegative2 (2%)1 (2%)1 (2%)FE0.361NSPoly Arthritis24 (24%)9 (18%)15 (30%)Poly Arthralgia74 (74%)40 (80%)34 (68%)Photosensitivity49 (49%)24 (48%)25 (50%)X2 = 0.040.841NSAlopecia51 (51%)29 (58%)22 (44%)X2 = 1.9610.161NSConstitutional symptoms80 (80%)43 (86%)37 (74%)X2 = 2.250.134NSSerositis (pleural or pericardial effusion)39 (39%)11 (22%)28 (56%)X2 = 12.15<0.001HSNeuropsychiatric manifestations22 (22%)5 (10%)17 (34%)X2 = 8.3920.004SRecurrent thrombosis12 (12%)8 (16%)4 (8%)FE0.357NSBleeding tendency6 (6%)5 (10%)1 (2%)FE0.204NSCardiac manifestation20 (20%)7 (14%)13 (26%)X2 = 2.250.134NSPulmonary manifestations33 (33%)8 (16%)25 (50%)X2 = 13.07<0.001STLC x 103 /µL5.26 ± 2.3(1.8 - 13)5.53 ± 2.27(2.7 - 13)5 ± 2.34(1.8 - 13)t= 1.1430.256NSNeutrophils x 103 /µL3.24 ± 1.47(1 - 8)3.32 ± 1.5(1 - 7)3.17 ± 1.44(1 - 8)t= 0.5130.609NSLymphocytes x 103 /µL1.38 ± 0.68(0.2 - 3.5)1.43 ± 0.59(0.2 - 3)1.33 ± 0.76(0.5 - 3.5)t= 0.7480.456NSHGB (g/dL)10.42 ± 1.56(7.2 - 13.8)10.88 ± 1.48(7.2 - 13.8)9.96 ± 1.51(7.5 - 13)t= 3.0860.003SPLT x 103 /µL231.27 ± 80.38(25 - 452)218.5 ± 79.29(25 - 406)244.04 ± 80.22(105 - 452)t= -1.6010.113NSESR (mm/hr)(Median (IQR))40 (30 - 60)(5 - 140)30 (22 - 40)(5 - 140)60 (40 - 60)(13 - 140)z= -4.379<0.001HSCRP (mg/L)(Median (IQR))6 (6 - 12)(0.4 - 96)6 (4 - 6)(0.4 - 56)12 (6 - 48)(4 - 96)z= -5.373<0.001HSUrine analysisRed Blood cells (RBCS)2 (1 - 3)(0 - 6)2 (1 - 2)(0 - 4)2 (1 - 4)(0 - 6)z= -2.8610.004SPus cells3 (2 - 3)(0 - 8)2 (1 - 3)(0 - 4)3 (3 - 5)(0 - 8)z= -5.405<0.001HS Urinary Casts(N, %)NIL85 (85%)50 (100%)35 (70%)FE<0.001HSPositive15 (15%)0 (0%)15 (30%)Albumin(N, %) by dipstickNIL47 (47%)45 (90%)2 (4%)FE<0.001HS(+)20 (20%)5 (10%)15 (30%)(++)22 (22%)0 (0%)22 (44%)(+++)11 (11%)0 (0%)11 (22%)24-hour Urinary proteins (mg/24h)400 (150 - 1000)(100 - 12000)200 (100 - 200)(100 - 400)1000 (600 - 2000)(100 - 12000)z= -8.180<0.001HSBUN (mg/dL)21.47 ± 10.55(12 - 98)18.74 ± 1.26(15 - 22)24.2 ± 14.43(12 - 98)t= -2.6650.010SSerum creatinine (mg/dL)1.07 ± 1.13(0.3 - 5.5)0.6 ± 0.17(0.3 - 1)1.53 ± 1.46(0.4 - 5.5)t= -4.487<0.001HSeGFR (mL/min/1.73m2)80.87 ± 19.85(25 - 96)88.96 ± 7.25(72 - 96)72.78 ± 24.7(25 - 96)t= 4.445<0.001HSC3 (mg/dL)95.5 (65.5 - 134)(27 - 170)121 (95 - 135)(27 - 169)69 (62 - 96)(45 - 170)z= -4.748<0.001HSC4 (mg/dL)13.5 (8 - 22)(5 - 42)22 (14 - 23)(5 - 42)8 (6 - 12)(6 - 33)z= -5.883<0.001HSLACNegative91 (91%)43 (86%)48 (96%)FE0.16NSPositive9 (9%)7 (14%)2 (4%)A.C. LNegative93 (93%)45 (90%)48 (96%)FE0.436NSPositive7 (7%)5 (10%)2 (4%)Anti DNANegative8 (8%)5 (10%)3 (6%)FE0.715NSPositive92 (92%)45 (90%)47 (94%)Anti DNA (IU/mL)22.97 ± 7.76(10 - 36)18.02 ± 4.77(10 - 34)27.92 ± 6.99(10 - 36)t= -8.277<0.001HSANANegative1 (1%)1 (2%)0 (0%)FE1.00NSPositive99 (99%)49 (98%)50 (100%)Renal biopsy Classes(N, %)Not done50 (50%)50 (100%)0 (0%)FE<0.001HSClass II3 (6%)0 (0%)3 (6%)Class III18 (36%)0 (0%)18 (36%)Class IV13 (26%)0 (0%)13 (26%)Class V13(26%)0 (0%)13(26%)Class VI3 (6%)0 (0%)3 (6%)A.I (/24)0 (0 - 2)(0 - 12)0 (0 - 0)(0 - 1)2 (0 - 7)(0 - 12)z= -6.075<0.001HSC.I (/12)0 (0 - 1)(0 - 8)0 (0 - 0)(0 - 1)1 (0 - 2)(0 - 8)z= -5.898<0.001HSR-SLEDAI0 (0 - 8)(0 - 12)0 (0 - 0)(0 - 0)8 (4 - 8)(0 - 12)z= -9.037<0.001HSSLEDAI-2K SCORE6 (1 - 10)(0 - 16)1 (0 - 4)(0 - 11)10 (8 - 11)(0 - 16)z= -7.142<0.001HSSLEDAI-2K SCORE (N, %)In active (0)23 (23%)42 (84%)1 (2%)FE<0.001HSMild (1 – 5)22 (22%)3 (6%)2 (4%)Moderate (6 – 10)32 (32%)5 (10%)27 (54%)Severe (11 - 19)23 (23%)0 (0%)20 (40%)CXCL10 (pg/mL)217.39 ± 124.82(50 - 580)121 ± 40.61(50 - 220)313.78 ± 104.24(120 - 580)t= -12.185<0.001HSFrequency of drug intake (N, %)Prednisolone (N, %)100 (100%)50 (100%)50 (100%)N/AN/A---Hydroxychloroquine (N, %)100 (100%)50 (100%)50 (100%)N/AN/A---Azathioprine (N, %)85 (85%)46 (92%)39 (78%)t = 1.980.051NSCyclophosphamide (N, %)30 (30%)4 (8%)26 (52%)t=-5.42< 0.001HSMycophenolate mofetil (N, %)25 (25%)3 (6%)22 (44%)t=-4.78< 0.001HSRituximab (N, %)3 (3%)0 (0%)3 (6%)t=-1.770.083NSP value > 0.05: non-significant (NS); P value < 0.05: significant (S); P value < 0.01: highly significant (HS)TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, LAC lupus anticoagulant, ACL Anticardiolipin, ANA antinuclear antibody, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity scoreSLEDAI-2K systemic lupus erythematosus disease activity scoreFisher’s Exact test of significance (FE). Mann-Whitney test of significance (z). Chi-Square test of significance (X2) Comparison between two groups as regards demographic data, cumulative clinical data, laboratory data, disease activity scores, and level of serum CXCL10 217.39 ± 124.82 (50 - 580) 121 ± 40.61 (50 - 220) 313.78 ± 104.24 (120 - 580) P value > 0.05: non-significant (NS); P value < 0.05: significant (S); P value < 0.01: highly significant (HS) TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, LAC lupus anticoagulant, ACL Anticardiolipin, ANA antinuclear antibody, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity score SLEDAI-2K systemic lupus erythematosus disease activity score Fisher’s Exact test of significance (FE). Mann-Whitney test of significance (z). Chi-Square test of significance (X2) SDI was significantly higher in LN patients (Group II) compared to non-nephritis patients (Group I), with median scores of 1 and 0, respectively (p < 0.001). While renal and neurological damage were significantly more prevalent in the LN group (p < 0.001), other parameters, including ocular, pulmonary, cardiac, and musculoskeletal damage, showed no significant differences between groups (p > 0.05), as illustrated in Table 2.Table 2Comparison between the two groups as regards the damage index parameters and their scoreTotal Study group(n = 100)GroupsFisher’s Exact testGroup ISLE patients without nephritis (n = 50)Group IILNpatients(n = 50)N (%)N (%)N (%)p-valueSig.OcularNo99 (99%)49 (98%)50 (100%)1.00NSYes (1)1 (1%)1 (2%)0 (0%)Neurological077 (77%)46 (92%)31 (62%)<0.001HS120 (20%)3 (6%)17 (34%)23 (3%)1 (2%)2 (4%)PulmonaryNo97 (97%)49 (98%)48 (96%)1.00NSYes (1)3 (3%)1 (2%)2 (4%)CardiacNo91 (91%)47 (94%)44 (88%)0.487NSYes (1)9 (9%)3 (6%)6 (12%)Renal074 (74%)50 (100%)24 (48%)<0.001HS120(20%)0 (0%)20(40%)23 (3%)0 (0%)3 (6%)33 (3%)0 (0%)3 (6%)VascularNo98 (98%)48 (96%)50 (100%)0.495NSYes (1)2 (2%)2 (4%)0 (0%)GastrointestinalNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)SkinNo93 (93%)48 (96%)45 (90%)0.218NSYes (1)7 (7%)2 (4%)5 (10%)MusculoskeletalNo92 (92%)47 (94%)45 (90%)0.435NSYes (1)8 (8%)3 (6%)5 (10%)GonadalNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)EndocrinalNo94 (94%)49 (98%)45 (90%)0.204NSYes (1)6 (6%)1 (2%)5 (10%)MalignancyNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)Total damage score (SDI)Median (IQR)Range1(0 - 2)(0 - 4)0 (0 - 0)(0 - 3)1 (0 - 2)(0 - 4)<0.001*HSSDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage IndexP value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS)Renal damage was assessed using the renal domain of the SLICC/ACR Damage Index (SDI): 0 = none; 1 = proteinuria > 3.5 g/24 h OR GFR < 60 mL/min; 2 = both proteinuria and GFR criteria; 3 = End Stage Renal Disease (ESRD) Table 2Comparison between the two groups as regards the damage index parameters and their scoreTotal Study group(n = 100)GroupsFisher’s Exact testGroup ISLE patients without nephritis (n = 50)Group IILNpatients(n = 50)N (%)N (%)N (%)p-valueSig.OcularNo99 (99%)49 (98%)50 (100%)1.00NSYes (1)1 (1%)1 (2%)0 (0%)Neurological077 (77%)46 (92%)31 (62%)<0.001HS120 (20%)3 (6%)17 (34%)23 (3%)1 (2%)2 (4%)PulmonaryNo97 (97%)49 (98%)48 (96%)1.00NSYes (1)3 (3%)1 (2%)2 (4%)CardiacNo91 (91%)47 (94%)44 (88%)0.487NSYes (1)9 (9%)3 (6%)6 (12%)Renal074 (74%)50 (100%)24 (48%)<0.001HS120(20%)0 (0%)20(40%)23 (3%)0 (0%)3 (6%)33 (3%)0 (0%)3 (6%)VascularNo98 (98%)48 (96%)50 (100%)0.495NSYes (1)2 (2%)2 (4%)0 (0%)GastrointestinalNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)SkinNo93 (93%)48 (96%)45 (90%)0.218NSYes (1)7 (7%)2 (4%)5 (10%)MusculoskeletalNo92 (92%)47 (94%)45 (90%)0.435NSYes (1)8 (8%)3 (6%)5 (10%)GonadalNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)EndocrinalNo94 (94%)49 (98%)45 (90%)0.204NSYes (1)6 (6%)1 (2%)5 (10%)MalignancyNo100 (100%)50 (100%)50 (100%)Yes0 (0%)0 (0%)0 (0%)Total damage score (SDI)Median (IQR)Range1(0 - 2)(0 - 4)0 (0 - 0)(0 - 3)1 (0 - 2)(0 - 4)<0.001*HSSDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage IndexP value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS)Renal damage was assessed using the renal domain of the SLICC/ACR Damage Index (SDI): 0 = none; 1 = proteinuria > 3.5 g/24 h OR GFR < 60 mL/min; 2 = both proteinuria and GFR criteria; 3 = End Stage Renal Disease (ESRD) Comparison between the two groups as regards the damage index parameters and their score Median (IQR) Range 1(0 - 2) (0 - 4) 0 (0 - 0) (0 - 3) 1 (0 - 2) (0 - 4) SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS) Renal damage was assessed using the renal domain of the SLICC/ACR Damage Index (SDI): 0 = none; 1 = proteinuria > 3.5 g/24 h OR GFR < 60 mL/min; 2 = both proteinuria and GFR criteria; 3 = End Stage Renal Disease (ESRD) Table 3 clearly demonstrated that serum CXCL10 exhibited a significant positive correlation with 24-hour urinary protein (r 0.865, p < 0.001), BUN (r 0.368, p < 0.001), serum creatinine (r 0.459, p < 0.001), SLEDAI-2K (r 0.615, p < 0.001), R-SLEDAI (r 0.818, p < 0.001), SDI (r 0.45, p < 0.001), ESR, and CRP (p < 0.001). Conversely, it demonstrated a negative correlation with eGFR (r = −0.468, p < 0.001), hemoglobin (HGB) (r = −0.421, p < 0.001), consumed C3 (r = −0.295, p = 0.003), and C4 levels (r = −0.546, p < 0.001). No significant link was seen between serum CXCL10 and other laboratory measures such as white blood cells, lymphocytes, neutrophils, and platelet count.Table 3Correlation between serum CXCL10 and different laboratory findings, disease activity, and damage scoreCXCL10 (pg/mL)rp-valueSig.Disease duration (Years)0.1060.294*NSTLC x 103 /µL−0.0500.619**NSNeutrophils × 103 /µL0.0290.773**NSLymphocytes × 103 /µL−0.0160.875**NSHgb (g/dL)−0.421<0.001**HSPLT x 103 /µL0.0890.379**NSESR (mm/hr.)0.535<0.001*HSCRP (mg/L)0.529<0.001*HS24-hour Urinary proteins (mg/24 h)0.865<0.001*HSBUN (mg/dL)0.368<0.001**HSSerum creatinine (mg/dL)0.459<0.001**HSeGFR (mL/min/1.73 m2)−0.468<0.001**HSC3 (mg/dL)−0.2950.003*SC4 (mg/dL)−0.546<0.001*HSA.I (/24)0.565<0.001*HSC.I (/12)0.575<0.001*HSR-SLEDAI0.818<0.001*HSSLEDAI-2K SCORE0.615<0.001*HSTotal damage score (SDI)0.612<0.001*HSp value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS)TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity score, SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index, SLEADI-2K systemic lupus erythematosus disease activity score*Spearman’s rho test**Pearson’s test Table 3Correlation between serum CXCL10 and different laboratory findings, disease activity, and damage scoreCXCL10 (pg/mL)rp-valueSig.Disease duration (Years)0.1060.294*NSTLC x 103 /µL−0.0500.619**NSNeutrophils × 103 /µL0.0290.773**NSLymphocytes × 103 /µL−0.0160.875**NSHgb (g/dL)−0.421<0.001**HSPLT x 103 /µL0.0890.379**NSESR (mm/hr.)0.535<0.001*HSCRP (mg/L)0.529<0.001*HS24-hour Urinary proteins (mg/24 h)0.865<0.001*HSBUN (mg/dL)0.368<0.001**HSSerum creatinine (mg/dL)0.459<0.001**HSeGFR (mL/min/1.73 m2)−0.468<0.001**HSC3 (mg/dL)−0.2950.003*SC4 (mg/dL)−0.546<0.001*HSA.I (/24)0.565<0.001*HSC.I (/12)0.575<0.001*HSR-SLEDAI0.818<0.001*HSSLEDAI-2K SCORE0.615<0.001*HSTotal damage score (SDI)0.612<0.001*HSp value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS)TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity score, SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index, SLEADI-2K systemic lupus erythematosus disease activity score*Spearman’s rho test**Pearson’s test Correlation between serum CXCL10 and different laboratory findings, disease activity, and damage score p value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS) TLC total leucocytic count, PLT platelet count, HGB hemoglobin, ESR erythrocyte sedimentation rate, CRP C-reactive protein, Bun blood urea nitrogen, eGFR estimated glomerular filtration rate, C3 complement 3, C4 complement 4, AI activity index, CI chronicity index, Renal SLEDAI renal systemic lupus erythematosus disease activity score, SDI: Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index, SLEADI-2K systemic lupus erythematosus disease activity score *Spearman’s rho test **Pearson’s test In the univariate logistic regression analysis, several clinical and laboratory parameters were significantly associated with the presence of LN, including higher CXCL10 levels, lower eGFR, reduced complement levels (C3 and C4), and higher SLEDAI-2K scores, in addition to treatment regimens. Among these variables, CXCL10 showed a strong positive association with LN (OR = 1.06, 95% CI: 1.03–1.08; p < 0.001). To adjust for potential confounding by treatment and other clinical markers, a multivariate model was constructed. In this model, CXCL10 remained an independent indicator of LN, where each 10 pg/mL rise was associated with an 86% increase in the odds of active LN (adjusted OR = 1.86, 95% CI:1.19–2.90; p = 0.006). Notably, this significant association was maintained even after adjusting for the use of induction therapies, such as Cyclophosphamide and Mycophenolate Mofetil, as well as established markers like C3, C4, and SLEDAI-2K; this data has been presented in Table 4.Table 4Multiple regression analysis for significant predictors of LNItemUnivariate analysisMultivariate analysisOR (95% CI)p-valueOR (95% CI)p-valueCXCL10 (per 10 pg/mL)1.79 (1.34–2.15)<0.0011.86 (1.19–2.90)0.006eGFR (mL/min/1.73 m2)0.96 (0.93–0.98)<0.0011.08 (0.89–1.30)0.426C3 (mg/dL)0.97 (0.96–0.99)<0.0010.94 (0.88–1.00)0.059C4 (mg/dL)0.84 (0.78–0.90)<0.0010.94 (0.72–1.24)0.676SLEDAI-2K score1.66 (1.40–1.97)<0.0010.84 (0.52–1.36)0.472Anti-DNA (IU/mL)3.14 (0.60–16.38)0.17536.94 (0.01-143903.84)0.392Cyclophosphamide9.78 (3.31–28.91)<0.0015.05 (0.08–329.30)0.447Mycophenolate mofetil8.21 (2.54–26.51)<0.00110.81 (0.49–240.50)0.133P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS) eGFR: Estimated glomerular filtration rate, C3 complement 3, C4 complement 4, SLEDAI-2K systemic lupus erythematosus disease activity score, AntiDNA anti-double-stranded DNA antibodies Table 4Multiple regression analysis for significant predictors of LNItemUnivariate analysisMultivariate analysisOR (95% CI)p-valueOR (95% CI)p-valueCXCL10 (per 10 pg/mL)1.79 (1.34–2.15)<0.0011.86 (1.19–2.90)0.006eGFR (mL/min/1.73 m2)0.96 (0.93–0.98)<0.0011.08 (0.89–1.30)0.426C3 (mg/dL)0.97 (0.96–0.99)<0.0010.94 (0.88–1.00)0.059C4 (mg/dL)0.84 (0.78–0.90)<0.0010.94 (0.72–1.24)0.676SLEDAI-2K score1.66 (1.40–1.97)<0.0010.84 (0.52–1.36)0.472Anti-DNA (IU/mL)3.14 (0.60–16.38)0.17536.94 (0.01-143903.84)0.392Cyclophosphamide9.78 (3.31–28.91)<0.0015.05 (0.08–329.30)0.447Mycophenolate mofetil8.21 (2.54–26.51)<0.00110.81 (0.49–240.50)0.133P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS) eGFR: Estimated glomerular filtration rate, C3 complement 3, C4 complement 4, SLEDAI-2K systemic lupus erythematosus disease activity score, AntiDNA anti-double-stranded DNA antibodies Multiple regression analysis for significant predictors of LN P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS) eGFR: Estimated glomerular filtration rate, C3 complement 3, C4 complement 4, SLEDAI-2K systemic lupus erythematosus disease activity score, AntiDNA anti-double-stranded DNA antibodies The distribution of serum CXCL10 levels across different renal biopsy classes (II–VI) in LN group A clear upward trend is observed from Class II to Class V, with mean CXCL10 concentrations rising from 200 pg/mL in Class II to 240 pg/mL in Class III, 320 pg/mL in Class IV, and peaking at 420 pg/mL in Class V. A slight decline is noted in Class VI (330 pg/mL), with statistically significant difference among the classes (F = 11.9 p < 0.001), as presented in Fig. 1Fig. 1Distribution of serum CXCL10 among different renal biopsy classes in LN patients (N = 50) Distribution of serum CXCL10 among different renal biopsy classes in LN patients (N = 50) A ROC curve was constructed, and its AUC was calculated to assess the diagnostic utility of serum CXCL10 in LN and to ascertain its function as a biomarker of disease activity for both SLEDAI- 2K and R-SLEDAI. Cutoff values and performance parameters were delineated in Table 5a and Fig. 2a–c.Fig. 2a Serum CXCL10 as a predictor of lupus nephritis. b. Serum CXCL10 as a predictor of renal SLEDAI (R-SLEDAI). c. Serum CXCL10 as a predictor of disease activity score (SLEDAI) a Serum CXCL10 as a predictor of lupus nephritis. b. Serum CXCL10 as a predictor of renal SLEDAI (R-SLEDAI). c. Serum CXCL10 as a predictor of disease activity score (SLEDAI) A serum CXCL10 level exceeding 180 pg/ml was indicative of LN, demonstrating 96% sensitivity, 94% specificity, 94.1% positive predictive value (PPV), 95.9% negative predictive value (NPV), and an AUC of 0.974. At the identical cut-off point, it serves as a predictor for both R-SLEDAI (100% sensitivity, 94.23% specificity, 94.1% PPV, 100% NPV with an AUC of 0.992) and the SLEDAI-2K score (81.97% sensitivity, 97.44% specificity, 98% PPV, 77.6% NPV with an AUC of 0.906). Internal validation via bootstrapping confirmed the high diagnostic accuracy of CXCL10 (AUC 0.974; 95% CI: 0.94–1.00) at a cutoff of 180 pg/mL, as illustrated in Table 5b Using the definition of active LN (24-hour proteinuria > 500 mg). Serum CXCL10 at >180 pg/ml achieved 97.1% sensitivity and 93.7% specificity (PPV 94%, NPV 95%). The base model (24 h urinary protein +eGFR+c3+c4+SLEDAI-2K) performed well, but the full model (base + CXCL10) showed further improvement in sensitivity, specificity, PPV, and NPV (96–98%, 94–96%, 93–96%, 97–99%), respectively, with AUC 0.98–0.99. This directly supports the added diagnostic value of CXCL10 beyond proteinuria, C3/C4, eGFR, and SLEDAI-2K, as shown in Table 5c Table 5aSerum CXCL10 as a predictor of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAICXCL10 (pg/mL)AUC95% CIp-valueCutoff valueSensitivitySpecificityPPVNPVLN0.9740.942 - 1.00<0.001>18096%94%94.10%95.90%R- SLEDAI0.9920.981 - 1.00<0.001>180100%94.23%94.10%100%SLEDAI-2K score0.9060.845–0.968<0.001>18081.97%97.44%98%77.6%P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Table 5bBootstrap ROC results at 180 pg/mL of serum CXCL10 for the prediction of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAICXCL10 (pg/mL)AUC (95% CI)Sensitivity (95% CI)Specificity (95% CI)PPV (95% CI)NPV (95% CI)LN0.974 (0.94–1.00)96% (90–100%)92% (84–98%)92% (84–98%)96% (90–100%)R-SLEDAI0.99 (0.97–1.00)100% (94–100%)94% (86–99%)94% (87–99%)100% (94–100%)SLEDAI-2K0.906 (0.85–0.96)82% (72–92%)95% (88–100%)92–95% (85–98%)85% (75–93%)AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Table 5cComparative diagnostic accuracy of CXCL10 and other established markers in predicting LNPredictorsAUC95% CICut off valuesensitivityspecificityPPVNPVp- valueSerum CXCL10 alone (pg/mL)0.9740.942–1>180 pg/ml96%94%94.1%95.9%<0.001Base model (24 h urinary protein +eGFR+c3+c4+SLEDAI- 2K)0.96–0.98-N/A92–95%90–94%88–92%93–96%<0.001Full model (CXCL10 +24 h urinary protein +eGFR+c3+c4+SLEDAI- 2K)0.98–0.99-N/A96–98%94–96%93–96%97–99%<0.001R-SLEDAI score (for reference)0.990.98–1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$0$$\end{document}100%94%94.1%100%<0.001P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: renal systemic lupus erythematosus disease activity score, eGFR: estimated glomerular filtration rate, C3: complement 3, C4: complement 4 Table 5aSerum CXCL10 as a predictor of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAICXCL10 (pg/mL)AUC95% CIp-valueCutoff valueSensitivitySpecificityPPVNPVLN0.9740.942 - 1.00<0.001>18096%94%94.10%95.90%R- SLEDAI0.9920.981 - 1.00<0.001>180100%94.23%94.10%100%SLEDAI-2K score0.9060.845–0.968<0.001>18081.97%97.44%98%77.6%P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Serum CXCL10 as a predictor of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAI P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Table 5bBootstrap ROC results at 180 pg/mL of serum CXCL10 for the prediction of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAICXCL10 (pg/mL)AUC (95% CI)Sensitivity (95% CI)Specificity (95% CI)PPV (95% CI)NPV (95% CI)LN0.974 (0.94–1.00)96% (90–100%)92% (84–98%)92% (84–98%)96% (90–100%)R-SLEDAI0.99 (0.97–1.00)100% (94–100%)94% (86–99%)94% (87–99%)100% (94–100%)SLEDAI-2K0.906 (0.85–0.96)82% (72–92%)95% (88–100%)92–95% (85–98%)85% (75–93%)AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Bootstrap ROC results at 180 pg/mL of serum CXCL10 for the prediction of lupus nephritis, disease activity (SLEDAI-2K), and R-SLEDAI AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: Renal systemic lupus erythematosus disease activity score Table 5cComparative diagnostic accuracy of CXCL10 and other established markers in predicting LNPredictorsAUC95% CICut off valuesensitivityspecificityPPVNPVp- valueSerum CXCL10 alone (pg/mL)0.9740.942–1>180 pg/ml96%94%94.1%95.9%<0.001Base model (24 h urinary protein +eGFR+c3+c4+SLEDAI- 2K)0.96–0.98-N/A92–95%90–94%88–92%93–96%<0.001Full model (CXCL10 +24 h urinary protein +eGFR+c3+c4+SLEDAI- 2K)0.98–0.99-N/A96–98%94–96%93–96%97–99%<0.001R-SLEDAI score (for reference)0.990.98–1\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$0$$\end{document}100%94%94.1%100%<0.001P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: renal systemic lupus erythematosus disease activity score, eGFR: estimated glomerular filtration rate, C3: complement 3, C4: complement 4 Comparative diagnostic accuracy of CXCL10 and other established markers in predicting LN P value > 0.05: non-significant (NS); p value < 0.05: significant (S); p value < 0.01: highly significant (HS). AUC: area under the curve, PPV: Positive Predictive Value, NPV: Negative Predictive Value, SLEDAI-2K: systemic lupus erythematosus disease activity score, R-SLEDAI: renal systemic lupus erythematosus disease activity score, eGFR: estimated glomerular filtration rate, C3: complement 3, C4: complement 4 Discussion SLE is a complex autoimmune connective tissue disease characterized by loss of immunological tolerance, production of autoantibodies, immune complex deposition, and inflammation. LN is a very extreme type of disease, which has immune-mediated kidney damage resulting in increased morbidity and mortality. LN clinical presentation ranges between moderate proteinuria and progressive glomerulonephritis with frequent complications of hematuria, hypertension, and renal failure [8, 15, 16, 17, 18]. The most accurate technique for diagnosing and classifying lupus nephritis is renal biopsy, which is invasive and cannot be repeated to assess disease activity. It is important to note that this limitation supports the use of non-invasive biomarkers capable of precisely revealing the presence of renal involvement and systemic disease activity in SLE [19, 20]. Notable examples include interferon-regulated chemokines, such as CXCL10, commonly known as IP-10. IFN-γ stimulates CXCL10, which binds to CXCR3 receptor on activated T cells, NK cells, and dendritic cells [21, 22]. The CXCL10–CXCR3 system facilitates the recruitment of immune cells to organs of inflammation, such as the kidneys, thereby exacerbating local inflammation and tissue damage [23]. Previous studies have also shown that CXCL10 is more likely to be increased in blood and urine in patients with SLE, which is associated with involvement of the kidneys and general activity of the disease [24, 25, 8]. In line with previous results, the current research evaluated serum CXCL10 of 100 Egyptian patients with SLE and compared it to that of those who did not exhibit renal involvement; the level of CXCL10 was significantly higher in patients with LN (p < 0.001). This supports the role of CXCL10 as a potential biomarker of renal inflammation and active disease. In our analysis, the LN group exhibited a markedly greater number of male patients, whereas age and disease duration were analogous between the groups. These findings largely contradict the research of Wang and Cui., which indicated no substantial demographic disparities. Wang and Cui also noted an extended disease duration in LN patients (4.93 ± 2.43 years) relative to non-nephritis cases (3.83 ± 2.17 years, p = 0.003) [8]. These inconsistencies may arise from ethnic, genetic, or environmental variability among the populations studied. Serositis, pulmonary, and neuropsychiatric manifestations were significantly more common in patients with LN, which confirms the results of Kosałka-Wegiel et al., who found a similar correlation between serositis accompanied by pleural and pericardial effusion and neuropsychiatric manifestations in LN [26]. The laboratory findings were high levels of 24-hour urine protein, serum creatinine, BUN, anti-dsDNA antibodies, and low levels of eGFR and complement (C3, C4) in the LN cohort. These results are consistent with previous studies that reported comparable results, meaning that patients with LN have higher SLEDAI-2K scores and renal impairment markers than those with non-renal SLE [8, 27]. The distribution of therapies in our cohort aligns with clinical guidelines, where potent immunosuppressants like Cyclophosphamide and Mycophenolate mofetil are selectively prioritized for patients with LN. This reflects the standard practice of using more intensive induction regimens to manage the increased disease burden associated with LN. Serum CXCL10 showed a significant association with the disease activity and kidney damage measures. There were positive correlations with 24-hour urine protein, BUN, serum creatinine, ESR, CRP, SLEDAI-2K, R-SLEDAI, and SLICC damage index, and inverse correlations with eGFR, hemoglobin, C3, and C4. These associations support the use of CXCL10 as a disease activity predictor and are strongly associated with cumulative damage. Abedi Azar et al. also reported significant correlations between the level of CXCL10 and lupus activity (r = 0.511, p < 0.05), and severity of the renal involvement (r = 0.656, p = 0.001) [27]. Shi et al. reported that it was positively correlated with CXCL10 and proteinuria, SLEDAI, but had an inverse correlation with C3, but not C4 or creatinine [28]. This was found in numerous cohorts. Wang and Cui found a positive correlation between the levels of serum CXCL10 and the scores of SLEDAI in patients with SLE and LN, and the results of the study by Zhang et al. showed that CXCL10 is significantly associated with disease activity (r = 0.416, p = 0.02) [8, 29]. These results were supported by a meta-analysis study by Puapatanakul et al., who found significantly raised CXCL10 levels in active versus inactive SLE (mean difference = 356.5 pg/mL, p = 0.019) and a pooled correlation coefficient of r = 0.29 (p < 0.001) [30]. Our data indicate an inverse link between CXCL10 and hemoglobin levels, consistent with the report by Rose et al., which identified a similar negative association (r = −0.315) [31]. Nonetheless, Hrycek et al. identified more negative associations between CXCL10 and subgroups of white blood cells, which we did not observe [32]. These discrepancies may indicate differences in disease stage or cytokine environment across patient groups. In accordance with Akhil et al., who proposed that IFN-regulated chemokines, including CXCL10, MCP-1, and MIP-3B, could forecast disease activity and exacerbations in SLE, our results endorse the clinical relevance of monitoring CXCL10 [33]. We further established that renal and neurological damage scores, evaluated using SLICC/ACR indices, were markedly elevated in LN patients and had a positive correlation with CXCL10 levels (r = 0.45, p < 0.001). This conclusion aligns with the findings of Geneva-Popova et al., who identified persistent increases of CXCL10 and other chemokines correlated with increased SLICC scores over time, suggesting that continuous CXCL10 expression may signify ongoing organ damage and disease development [24]. Strong association between serum CXCL10 and SDI scores, reflecting its association with cases with severe and prolonged disease Despite a strong association between serum CXCL10 and SDI, it is important to distinguish between the biological processes represented by CXCL10 and SDI. While CXCL10 is a dynamic marker of active Th1-driven inflammation, the SDI captures permanent, non-reversible organ damage. The association observed between these two metrics in our cohort likely reflects the cumulative impact of recurrent inflammatory episodes; patients with high disease activity (marked by elevated CXCL10) are at a higher risk for progressive structural damage over time. Therefore, CXCL10 serves as a marker of the active inflammatory state that eventually drives the accrual of damage recorded by the SDI. CXCL10 expression correlates with the histopathological severity of renal biopsy as serum CXCL10 levels was significantly increased among Class III and Class IV (proliferative LN), also among class V (membranous GN) compared to class II which had lowest level (p < 0.001) with a significant correlation with both AI and CI (r 0.565 p < 0.001, r 0.575 p < 0.001) of renal biopsy. These results demonstrate that serum CXCL10 rises in parallel with proliferative and membranous nephritis patterns, suggesting that it mirrors the degree of intrarenal immune activation and may serve as a non-invasive indicator of renal pathology activity. Our results aligned with those of previous studies [7, 34, 35], which concluded that CXCL10 is strongly associated with active LN and ongoing glomerular damage can also serve as a promising test for monitoring LN and differentiating between LN classifications. A moderate decline was observed in Class VI (330 pg/mL), likely reflecting extensive sclerotic change and reduced active inflammation. Serum CXCL10 was correlated with the cumulative damage score and CI of renal biopsy (p < 0.001), which was matched with other studies that found that persistent elevation of CXCL10 despite clinical remission has been linked to subclinical activity and future flares, emphasizing its potential use as a biomarker for monitoring treatment response and prognosis [7, 36]. These findings may be related to the role of the CXCL10–CXCR3 axis, which drives recruitment of CXCR3+ T cells and other inflammatory leukocytes into the kidney, thereby promoting the histologic lesions and fibrotic remodelling that underlie poor long-term renal outcomes; preclinical work also demonstrates that modulation of this axis alters renal immune cell trafficking and impacts therapeutic responses [23]. The findings from this study identify CXCL10 as a statistically significant independent factor associated with LN among the variables tested in the multivariate analysis. While univariate analysis initially suggested associations with eGFR, C3, C4, and the SLEDAI-2K score, as well as specific treatment regimen, these effects did not maintain statistical significance after adjusting for confounders in the final model. The association for CXCL10 (OR 1.86 per 10 pg/mL increase, p = 0.006) remained statistically stable even after adjusting for the use of potent induction therapies, such as Cyclophosphamide and Mycophenolate Mofetil, suggesting its potential as an independent indicator of renal involvement. This effect size is clinically meaningful, indicating that even modest elevations in CXCL10 are linked to substantially higher LN risk. eGFR, reduced complement levels, SLEDAI-2K score, and anti-dsDNA levels did not retain statistical significance after adjustment, indicating that their associations with LN may be confounded by disease activity or other overlapping factors. This suggests that elevated CXCL10 reflects a specific inflammatory pathway in the pathogenesis of LN that is distinct from broader measures of systemic SLE activity or traditional biomarkers like anti-DNA antibodies and complement levels. These results are consistent with previous research, such as that by Marie et al., who determined CXCL10 to be a sensitive non-invasive biomarker of LN activity [34]. However, caution is warranted, as other studies, such as Jakiela et al., found no evidence that chemokine markers were superior to proteinuria in distinguishing between active and inactive LN [37]. Therefore, these results underscore the potential clinical utility of CXCL10 as an additional, supportive biomarker for identifying or monitoring renal involvement in SLE patients, rather than a replacement A ROC curve study validated the diagnostic efficacy of CXCL10, with an optimal threshold of >180 pg/mL, resulting in 96% sensitivity and 94% specificity (AUC = 0.974) for diagnosing LN. Notably, the addition of CXCL10 to conventional established renal markers, including proteinuria, complement levels, and the SLEDAI-2K score, modestly improved overall diagnostic accuracy, supporting its incremental value in multivariable models. This finding is clinically relevant, as CXCL10 may reflect underlying inflammatory activity and could aid in the early identification of renal involvement. This threshold also forecasted R-SLEDAI and SLEDAI-2K with considerable precision (AUC = 0.992 and 0.906, respectively). The values exceed those documented by Wang and Cui (AUC = 0.75) and Marie et al.(AUC = 0.90), and are significantly greater than those reported by Choe et al., where both serum and urinary IP-10 demonstrated only moderate diagnostic efficacy (AUC = 0.595 and 0.519) [8, 34, 38]. These differences in higher values may be related to cross-sectional, single-center, and sample size. Zhang et al. identified serum CXCL10 as effective in separating active from inactive systemic lupus erythematosus (SLE) (AUC = 0.753, p = 0.007), but not in distinguishing LN from non-LN cases [29]. Also, Gohary et al. (AUC (95% CI) = 0.633 (0.430- 0.837), potentially due to their limited, all-female population [39]. Abediazar et al. also reported moderate accuracy (AUC = 0.691, sensitivity = 88%, specificity = 52%) [27]. These disparities highlight the impact of ethnicity, gender distribution, and cohort size on biomarker efficacy. Our data collectively indicate that serum CXCL10 correlates with both renal and systemic disease activity in SLE, potentially serving as a sensitive, non-invasive potential biomarker for the identification of LN. Moreover, its correlation with accumulated damage underscores the possibility for longitudinal disease surveillance. Limitations The present study has several limitations that warrant consideration. First, its cross-sectional design precludes the assessment of causality or temporal dynamics during disease exacerbation and remission. Second, as a single-center study involving an Egyptian cohort, the results may not be fully generalizable to other populations. Third, the absence of a healthy control group prevented the establishment of a baseline; however, our primary focus was the clinically relevant differentiation of active LN and SLE patients without renal involvement. Finally, the lack of detailed data on corticosteroid exposure is a limitation, as glucocorticoids can suppress IFN-γ–inducible chemokines like CXCL10, which may have influenced the observed concentrations. Future multicentric, longitudinal studies with larger sample sizes are required to validate the predictive utility of CXCL10 and to establish standardized cutoff values for clinical and therapeutic applications. Future directions Subsequent studies should aim to corroborate these findings through extensive, multicenter, and longitudinal investigations that encompass a variety of ethnic groups and disease stages. Incorporating serum CXCL10 evaluation into standard clinical monitoring may be investigated to determine its efficacy in forecasting renal flares, treatment outcomes, and long-term prognosis. Furthermore, the integration of CXCL10 with other IFN-γ–inducible chemokines, such as CXCL9 and CXCL11, or with other molecular and imaging biomarkers, may enhance diagnostic precision and risk assessment in lupus nephritis. Ultimately, molecular investigations of the CXCL10–CXCR3 signaling pathway may provide prospective therapeutic targets for alleviating renal inflammation and enhancing outcomes in people with SLE. Conclusion Serum CXCL10 shows promise as a potential biomarker for LN and disease activity, and being correlated to damage can also be used as a useful tool for determining the severity of the disease; however, further multicentric, longitudinal studies are required.